Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone
| Autor: | Tadashi Kimura, Seiji Mabuchi, Chie Kuragaki, Toshiya Yamamoto, Takayuki Enomoto, Fumiaki Isohashi, Kumiko Temma, Ken-ichirou Morishige, Hiromi Ugaki, Namiko Yada-Hashimoto, Kiyoshi Yoshino, Takashi Takeda, Takehiro Inoue, Nakajima Ryuichi, Yasuo Yoshioka |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Organoplatinum Compounds
FIGO Stage IIIB medicine.medical_treatment Brachytherapy Uterine Cervical Neoplasms Antineoplastic Agents Disease-Free Survival chemistry.chemical_compound Medicine Humans Nedaplatin External beam radiotherapy Aged Neoplasm Staging Retrospective Studies Cervical cancer business.industry Obstetrics and Gynecology Retrospective cohort study Middle Aged medicine.disease Combined Modality Therapy High-Dose Rate Brachytherapy Radiation therapy Treatment Outcome Reproductive Medicine chemistry Carcinoma Squamous Cell Female business Nuclear medicine Chemoradiotherapy |
| Zdroj: | Gynecologic and obstetric investigation. 69(4) |
| ISSN: | 1423-002X |
| Popis: | Objectives: The aim of this study was to evaluate whether nedaplatin-based concurrent chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) is superior to radiotherapy (RT) alone in patients with FIGO stage IIIb cervical cancer. Methods: The records of 41 consecutive women treated either with nedaplatin-based CCRT using HDR-ICBT (n = 20) or RT alone (nonrandomized control group, n = 21) for stage IIIb cervical cancer were retrospectively reviewed. The activity and toxicity were compared between the two treatment groups. Progression-free survival (PFS) and overall survival (OS) were the main endpoints. Results: The 5-year overall survival rates in the CCRT and RT groups were 65 and 33.3%, respectively. The median OS of the CCRT and RT groups were 60 and 29 months, respectively. CCRT was significantly superior to RT alone with regard to PFS (p = 0.0015) and OS (p = 0.0364). The frequency of acute grade 3–4 toxicity was significantly higher in the CCRT group than in the RT group. However, no statistically significant difference was observed with regard to severe late toxicity. Conclusions: Nedaplatin-based concurrent chemoradiotherapy was safely performed and significantly improved the prognosis of patients with FIGO stage IIIb cervical cancer. This treatment can be considered as an alternative to cisplatin-based chemoradiotherapy in this patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|